Sign In
Buy CMPX
$2.10
+0.0200 (+0.96%)
At Close: Jun 03, 2026
Compass Therapeutics to Participate in Upcoming September Investor Events
08:00am, Tuesday, 26'th Aug 2025
BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based
Compass Therapeutics: Finding Their Way With More Positive Updates In BTC
09:40am, Wednesday, 13'th Aug 2025
Compass Therapeutics' pipeline shows promise, especially with tovecimig's positive phase 2 results in biliary tract cancers and upcoming basket study plans. CTX-8371's early signals in NSCLC and TNBC
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
10:28pm, Tuesday, 12'th Aug 2025
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based
Compass Therapeutics Announces Proposed Public Offering
04:01pm, Tuesday, 12'th Aug 2025
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based
Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update
07:00am, Monday, 11'th Aug 2025
BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, to
Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025
04:01pm, Friday, 08'th Aug 2025
BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, wi
Squarepoint Ops LLC Acquires New Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)
03:36am, Wednesday, 11'th Jun 2025
Squarepoint Ops LLC acquired a new stake in Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
08:00am, Wednesday, 28'th May 2025
BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, tod
Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers
09:51pm, Monday, 12'th May 2025
Compass Therapeutics' tovecimig shows promise in biliary tract cancer with a 17.1% response rate, but further survival data is crucial for potential approval. CMPX's cash runway extends into early 202
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update
08:00am, Thursday, 08'th May 2025
Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (OR
Compass Therapeutics to Participate in Upcoming May Investor Events
08:00am, Tuesday, 06'th May 2025
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, tod
CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors. Combining CTX-471 with tovecimig (CTX-009) markedly increased an
2 Penny stocks to buy in May 2025
09:17am, Sunday, 27'th Apr 2025
Summary ⚈ Market conditions in May create opportunities for penny stock investors.⚈ Compass Therapeutics and Blade Air Mobility are highlighted for strong growth prospects.
BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, a
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
04:05pm, Wednesday, 02'nd Apr 2025
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
